Author:
Kow Chia Siang,Ramachandram Dinesh Sangarran,Hasan Syed Shahzad
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Biochemistry,Physiology
Reference8 articles.
1. Wu X, Xiang M, Jing H, Wang C, Novakovic VA, Shi J (2023) Damage to endothelial barriers and its contribution to long COVID. Angiogenesis 2023:1–18
2. Kow CS, Ramachandram DS, Hasan SS (2022) The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother 28(2):257–265
3. Zuily S, Lefèvre B, Sanchez O et al (2023) Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine 60:102031
4. Aman J, Duijvelaar E, Botros L, et al (2021) Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial [published correction appears in Lancet Respir Med. 2021 Aug;9(8):e84]. Lancet Respir Med 9(9):957–968
5. de Brabander J, Duijvelaar E, Schippers JR et al (2022) Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. Eur Respir J 60(6):2200780